Sea Spine Holdings Corp SPNE
We take great care to ensure that the data presented and summarized in this overview for SeaSpine Holdings Corp is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding SPNE
View all-
Rothschild & CO Asset Management Us Inc. New York, NY440KShares$00.06% of portfolio
-
Monarch Partners Asset Management LLC241KShares$00.61% of portfolio
-
Havens Advisors LLC New York, NY84.9KShares$01.83% of portfolio
-
Concourse Financial Group Securities, Inc. Birmingham, AL0Shares$00.0% of portfolio
Latest Institutional Activity in SPNE
Top Purchases
Top Sells
About SPNE
SeaSpine Holdings Corporation, a medical technology company, focuses on the design, development, and commercialization of surgical solutions for the treatment of spinal disorders in the United States and internationally. It offers orthobiologics and spinal implant solutions for the neurosurgeons and orthopedic spine surgeons to perform fusion procedures in the lumbar, thoracic, and cervical spine. The company's orthobiologics products include demineralized bone matrix (DBM), collagen ceramic matrices, demineralized cancellous allograft bone products, and synthetic bone void fillers to improve bone fusion rates in a range of orthopedic surgeries, including spine, hip, and extremities procedures. It also offers orthobiologics products in various forms, such as fibers, putties, pastes, strips, and DBM. In addition, the company offers implant products for spinal decompression, alignment, stabilization, and image-guided surgical solutions, as well as a surgical navigation system used to facilitate fusion in degenerative, minimally invasive, and complex spinal deformity procedures throughout the lumbar, thoracic, and cervical regions of the spine. SeaSpine Holdings Corporation was incorporated in 2015 and is headquartered in Carlsbad, California.
Insider Transactions at SPNE
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Jan 05
2023
|
John B Henneman Iii Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
82,654
-100.0%
|
-
|
Jan 05
2023
|
Michael Fekete Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
111,966
-100.0%
|
-
|
Jan 05
2023
|
Renee Gaeta Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
36,056
-100.0%
|
-
|
Jan 05
2023
|
Shweta Maniar Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
23,993
-100.0%
|
-
|
Jan 05
2023
|
Angela Steinway Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
23,725
-100.0%
|
-
|
Jan 05
2023
|
Kirtley C. Stephenson Director |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
9,700
-100.0%
|
-
|
Jan 05
2023
|
Kirtley C. Stephenson Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
128,640
-100.0%
|
-
|
Jan 05
2023
|
Keith Valentine Chief Executive Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
333,797
-100.0%
|
-
|
Jan 05
2023
|
John J. Bostjancic Chief Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
102,563
-100.0%
|
-
|
Jan 05
2023
|
Paul S. Benny VP, Treasurer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
20,950
-100.0%
|
-
|
Jan 05
2023
|
Dennis Cirino SVP, Global Spinal Systems |
SELL
Sale (or disposition) back to the issuer
|
Direct |
48,556
-100.0%
|
-
|
Jan 05
2023
|
Patrick L Keran SVP, General Counsel |
SELL
Sale (or disposition) back to the issuer
|
Direct |
69,628
-100.0%
|
-
|
Jan 05
2023
|
Tyler Lipschultz SVP, Orthobiologics and BD |
SELL
Sale (or disposition) back to the issuer
|
Direct |
131,284
-100.0%
|
-
|
Jan 05
2023
|
John J. Winge Vice President, Sales |
SELL
Sale (or disposition) back to the issuer
|
Direct |
90,951
-100.0%
|
-
|
Jan 05
2023
|
Stuart Essig Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
460,275
-100.0%
|
-
|
Jan 05
2023
|
Keith Bradley Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
88,592
-100.0%
|
-
|
Jan 01
2023
|
Keith Valentine Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,170
-2.1%
|
$57,360
$8.35 P/Share
|
Jan 01
2023
|
Keith Valentine Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,183
+3.45%
|
-
|
Jan 01
2023
|
John J. Bostjancic Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,281
-3.1%
|
$26,248
$8.35 P/Share
|
Jan 01
2023
|
John J. Bostjancic Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,575
+5.0%
|
-
|